Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil

Biochemical Pharmacology

Volumn 53, Issue 11, 1997, Pages 1613-1619

  Guitton, Jérôme ^a   Buronfosse, Thierry ^b   Désage, Michel ^a   Lepape, Alain ^c   Brazier, Jean Louis ^a   Beaune, Philippe ^d  

^a UNIVERSITÉ LYON 1   (France)

^b U Toxicologie Metabolique d'E   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Alfentanil; Analgesic drugs; CYP3A4; Drug metabolism; Fentanyl; Sufentanil

Indexed keywords

ALFENTANIL; CYTOCHROME P450; FENTANYL; SUFENTANIL;

AEROBIC METABOLISM; ANALGESIA; ARTICLE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; IMMUNOREACTIVITY; PHARMACOGENETICS; PRIORITY JOURNAL; YEAST;

ALFENTANIL; BENZOFLAVONES; COUMARINS; CYTOCHROME P-450 ENZYME SYSTEM; DITIOCARB; FENTANYL; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MICROSOMES, LIVER; SACCHAROMYCES CEREVISIAE; SUFENTANIL; TRANSFECTION;

EID: 0030739468     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00893-3     Document Type: Article

References (49)

1. Clotz MA and Nahata MC, Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharmacy 10: 581-593, 1991.
2. Mather LE, Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 8: 422-446, 1983.
3. Maine PO, Vozeh S, Heykants J, Thomson DA and Stanski DR, Population pharmacokinetics of alfentanil: The average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 66: 3-12, 1987.
4. Lavrijsen KM, Van Houdt JMG, Van Dyck MJ, Hendrickx JJJM, Woestenborghs RJH, Lauwers W, Meuldermans WEG and Heykants JJP, Is the metabolism of alfentanil subject to debrisoquine polymorphism? Anesthesiology 69: 535-540, 1988.
5. Henthorn TK, Spina E, Dumont E and Von Bahr C, In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics. Anesthesiology 70: 339-342, 1989.
6. Kharasch ED and Thummel KE, Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth Analg 76: 1033-1039, 1993.
7. Yun CH, Wood M, Wood AJ-J and Guengerich FP, Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4. Anesthesiology 77: 467-474, 1992.
8. Schellens JHM, Soons PA and Briemer DD, Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 37: 2507-2510, 1988.
9. Meuldermans W, Hendrickx J, Lauwers W, Hurkmans R, Swysen E, Thijssen J, Timmerman P, Woestenborghs R and Heykants J, Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab Dispos 15: 905-913, 1987.
10. Lavrijsen K, Van Houdt J, Van Dick D, Hendrickx J, Lauwers W, Hurkmans R, Bockx M, Janssen C, Meuldermans W and Heykants J, Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans. Drug Metab Dispos 18: 704-710, 1990.
11. Kharasch ED, Hill HF and Eddy AC, Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. Anesthesiology 75: 520-524, 1991.
12. Janicki PK, James MFM and Erskine WAR, Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. Br J Anaesth 68: 311-312, 1992.
13. Gill SS, Wright EM and Reilly CS, Pharmacokinetic interaction of propofol and fentanyl: Single bolus injection study. Br J Anaesth 65: 760-765, 1990.
14. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T and Guzelian PS, Comparaison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA activity. Clin Pharmacol Ther 52: 265-273, 1992.
15. Bartkowski RR, Goldberg ME, Huffnagle S and Epstein RH, Effect of erythromycin on sufentanil metabolism: Differences from alfentanil. Anesth Analg 70: S 16, 1990.
16. Gonzalez FJ, In vitro systems for prediction of rates of drugs clearance and drug interactions. Anesthesiology 77: 413-415, 1992.
17. Kobayashi K, Chiba K, Tani M, Kuroiwa Y and Ishizaki T, Development and preliminary application of a high-performance liquid chromatographic assay for omeprazole metabolism in human liver microsomes. J Pharmaceutic Biomed Analysis 12: 839-844, 1994.
18. Kremers P, Beaune P, Cresteil T, De Graeve J, Columelli S, Leroux JP and Gielen JE, Cytochrome P450 monooxygenase activities in human and rat liver microsomes. Eur J Biochem 118: 599-606, 1981.
19. Hartree EF, Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 48: 422-427, 1972.
20. Omura T and Sato R, The carbon monoxide binding pigment of liver microsomes. Evidences for its hematoprotein nature. J Biol Chem 239: 2370-2378, 1964.
21. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF and Kharasch ED, Catalytic role of cytochrome P450 3A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 23: 490-496, 1995.
22. Goromaru T, Katashima M, Matsuura H and Yoshimura N, Metabolism of fentanyl in isolated hepatocytes from rat and guinea pig. Chem Pharmaceutic Bull 33: 3922-3928, 1985.
23. Maurice M, Emiliani S, Dalet-Beluche I, Delancourt J and Lange R, Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 200: 508-517, 1991.
24. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36: 89-96, 1989.
25. Drouet-Coassolo C, Aubert C, Coassolo P and Cano JP, Capillary gas chromatographic-mass spectrometric method for the identification and quantification of some benzodiazepines and their unconjugated metabolites in plasma. J Chromatogr Biomed Appl 487: 295-311, 1989.
26. Lopez-Garcia MP, Dansette PM, Valadon P, Amar C, Beaune PH, Guengerich FP, Mansuy D, Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies: Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur J Biochem 213: 223-232, 1993.
27. Newton DJ, Wang RW, Lu AYH, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: 154-158, 1995.
28. De Waziers P, Cugnenc PH, Yang CS, Leroux JP, Beaune PH, Cytochrome P450 isozymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Therap 253: 387-394, 1990.
29. Belloc C, Baird S, Cosme J, Lecoeur S, Gautier J-C, Challine D, De Waziers I, Flinois J-P, Beaune P, Human cytochromes P450 expressed in Escherichia coli: Production of specific antibodies. Toxicology 106: 207-219, 1996.
30. Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S, Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography-mass spectrometry. Anesthesiology 61: 73-77, 1984.
31. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Therap 57: 16-24, 1995.
32. Pearce R, Greenway D, Parkinson A, Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol and testosterone oxidation. Arch Biochem Biophys 298: 211-225, 1992.
33. Guengerich FP, Turvey CG, Comparaison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Therap 256: 1189-1194, 1991.
34. Tateishi T, Krivoruk Y, Ueng Y-F, Wood AJJ, Guengerich FP, Wood M, Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82: 167-172, 1996.
35. Gonzalez FJ, Crespi CL, Gelboin HV, cDNA-expressed human cytochrome P450s: A new age of molecular toxicology and human risk assessment. Mutat Res 247: 113-127, 1991.
36. Kato R, Yamazoe Y, The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 4: 359-362, 1994.
37. Goldstein JA, De Morais SMF, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
38. Heim MH and Meyer, UA, Evolution of a highly polymorphic human cytochrome P450 genes cluster: CYP2D6. Genomics 14: 49-58, 1992.
39. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO, Specificity od substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Therap 265: 401-407, 1993.
40. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT and Van den Branden M, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38: 207-213, 1990.
41. Bartkowski RR, Goldberg M and Huffnagle S, Sufentanil disposition. Is it affected by erythromycin administration? Anesthesiology 78: 260-265, 1993.
42. Lehmann KA, Sipakis K, Gasparini R and Van Peer A, Pharmacokinetics of sufentanil in general surgical patients under different conditions of anesthesia. Acta Anesth Scand 37: 176-180, 1993.
43. Bartowski RR and McDonnell TE. Prolonged alfentanil effect following erythromycin administration. Anesthesiology 73: 566-568, 1990.
44. Hiller A, Olkkola KT, Isohanni P and Saarnivaara L, Unconsciousness associated with midazolam and erythromycin. Br J Anaesth 65: 826-828, 1990.
45. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M and Watkins PB, Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335: 11-15, 1990.
46. Mather LE, Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 8: 422-446, 1983.
47. Bower S and Hull CJ, Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 54: 871-877, 1982.
48. Ferrier C, Marty J, Bouffard Y, Haberer JP, Levron JC and Duvaldestin P, Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology 62: 480-484, 1985.
49. Gepts E, Shafer SL, Camu F, Stanski DR, Woestenborghs R, VanPeer A and Heykants JJP, Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology 83: 1194-1204, 1995.